FEATURES TREATMENT OF IDIOPATHIC OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY

Abstract

Introduction. The basis syndrome Overactive Bladder (OB) is detrusor overactivity (DO) – urodynamic concept that refers to spontaneous or provoked by involuntary detrusor contractions during the filling phase Bladder. Currently, there are two main forms of DO: neurogenic and idiopathic. The purpose was to evaluate the effectiveness of monotherapy with M-anticholinergic Tolterodine tartrate and its combined administration with the cyclic structural analogue of g-aminobutyric acid Gabantin in patients with idiopathic overactive bladder without detrusor overactivity (IOB). Object and methods. Patients were divided into two groups: group A – 31 patients (19 patients with IOB without Urinary Incontinence (UI) and 12 patients with UI and group B – 32 patients (21 patients with IOB without UI and 11 patients with UI). According to the study design, patients in group A were prescribed M-anticholinergic therapy Tolterodine tartra. Patients in group B received combined therapy with Tolterodin tartrate and Gabapentin for a total course for 8 weeks. Results and discussions. Analysis of the results in group A showed that this type of treatment does not lead to significant improvement. However, 3 patients (9.67 %) had a good result, and 7 patients (22.58 %) had a satisfactory result, the rest (21 patients, 67.74 %) had an unsatisfactory result. But among patients in the group B general, a satisfactory result of treatment was noted in 24 (75 %) patients. An unsatisfactory result was observed in 8 (25 %) patients. Conclusions. Monotherapy with M-anticholinergic in patients with IOB and the absence of DO has little effectiveness and is implemented mainly by reducing Pollakiuria. The symptoms of Urgency are resolved moderately (in 22.58 % of patients) and extremely rarely in full (in 9.67 % of patients). The proposed method of treatment by the combined administration of Tolterodine tartrate and Gabapentin allows to achieve a significantly more pronounced clinical effect manifested in a decrease in Pollakiuria by 64.17 %, Nocturia by 82.18 % and Urgency by 81.40% and UI by 80.66 %.